Cytokines in cutaneous lupus erythematosus

References

• Lee HJ, Sinha AA. Cutaneous lupus erythematosus: understanding of clinical features, genetic basis, and pathobiology of disease guides therapeutic strategies. Autoimmunity39(6), 433–444 (2006).
   Web of Science ®Google Scholar
• Millard TP, McGregor JM. Molecular genetics of cutaneous lupus erythematosus. Clin. Exp. Dermatol.26(2), 184–191 (2001).
   PubMed Web of Science ®Google Scholar
• Sestak AL, Furnrohr BG, Harley JB, Merrill JT, Namjou B. The genetics of systemic lupus erythematosus and implications for targeted therapy. Ann. Rheum. Dis.70(Suppl. 1), i37–i43 (2011).
   PubMed Web of Science ®Google Scholar
• Albrecht J, Taylor L, Berlin JA et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J. Invest. Dermatol.125(5), 889–894 (2005).
   PubMed Web of Science ®Google Scholar
• Kuhn A, Meuth AM, Bein D et al. Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus. Br. J. Dermatol.163(1), 83–92 (2010).
   PubMed Web of Science ®Google Scholar
• Kuhn A, Sticherling M, Bonsmann G. Clinical manifestations of cutaneous lupus erythematosus. J. Dtsch. Dermatol. Ges.5(12), 1124–1137 (2007).
   PubMedGoogle Scholar
• Al-Refu K, Goodfield M. Scar classification in cutaneous lupus erythematosus: morphological description. Br. J. Dermatol.161(5), 1052–1058 (2009).
   PubMedGoogle Scholar
• Lipsker D. The need to revisit the nosology of cutaneous lupus erythematosus: the current terminology and morphologic classification of cutaneous LE: difficult, incomplete and not always applicable. Lupus19(9), 1047–1049 (2010).
   Google Scholar
• Ronnblom L, Elkon KB. Cytokines as therapeutic targets in SLE. Nat. Rev. Rheumatol.6(6), 339–347 (2010).
   PubMed Web of Science ®Google Scholar
• Kuhn A, Bijl M. Pathogenesis of cutaneous lupus erythematosus. Lupus17(5), 389–393 (2008).
   PubMed Web of Science ®Google Scholar
• Wenzel J, Zahn S, Tuting T. Pathogenesis of cutaneous lupus erythematosus: common and different features in distinct subsets. Lupus19(9), 1020–1028 (2010).
   PubMed Web of Science ®Google Scholar
• Lin JH, Dutz JP, Sontheimer RD, Werth VP. Pathophysiology of cutaneous lupus erythematosus. Clin. Rev. Allergy Immunol.33(1–2), 85–106 (2007).
   PubMed Web of Science ®Google Scholar
• Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J. Immunol.172(5), 2731–2738 (2004).
   PubMed Web of Science ®Google Scholar
• Cho YN, Kee SJ, Lee SJ et al. Numerical and functional deficiencies of natural killer T cells in systemic lupus erythematosus: their deficiency related to disease activity. Rheumatology (Oxford)50(6), 1054–1063 (2011).
   PubMedGoogle Scholar
• Gabriel L, Morley BJ, Rogers NJ. The role of iNKT cells in the immunopathology of systemic lupus erythematosus. Ann. NY Acad. Sci.1173, 435–441 (2009).
   Google Scholar
• Wermeling F, Lind SM, Jordo ED, Cardell SL, Karlsson MC. Invariant NKT cells limit activation of autoreactive CD1d-positive B cells. J. Exp. Med.207(5), 943–952 (2010).
   PubMed Web of Science ®Google Scholar
• Franz B, Fritzsching B, Riehl A et al. Low number of regulatory T cells in skin lesions of patients with cutaneous lupus erythematosus. Arthritis Rheum.56(6), 1910–1920 (2007).
   PubMed Web of Science ®Google Scholar
• Antiga E, Del Bianco E, Difonzo EM, Fabbri P, Caproni M. Serum levels of the regulatory cytokines transforming growth factor-{β} and interleukin-10 are reduced in patients with discoid lupus erythematosus. Lupus20(6), 556–560 (2011).
   Google Scholar
• Crispin JC, Kyttaris VC, Terhorst C, Tsokos GC. T cells as therapeutic targets in SLE. Nat. Rev. Rheumatol.6(6), 317–325 (2010).
   PubMed Web of Science ®Google Scholar
• Wouters CH, Diegenant C, Ceuppens JL, Degreef H, Stevens EA. The circulating lymphocyte profiles in patients with discoid lupus erythematosus and systemic lupus erythematosus suggest a pathogenetic relationship. Br. J. Dermatol.150(4), 693–700 (2004).
   Google Scholar
• Wenzel J, Henze S, Brahler S, Bieber T, Tuting T. The expression of human leukocyte antigen-DR and CD25 on circulating T cells in cutaneous lupus erythematosus and correlation with disease activity. Exp. Dermatol.14(6), 454–459 (2005).
   Google Scholar
• Tebbe B, Mazur L, Stadler R, Orfanos CE. Immunohistochemical analysis of chronic discoid and subacute cutaneous lupus erythematosus – relation to immunopathological mechanisms. Br. J. Dermatol.132(1), 25–31 (1995).
   Google Scholar
• Al-Refu K, Goodfield M. Immunohistochemistry of ultrastructural changes in scarring lupus erythematosus. Clin. Exp. Dermatol.36(1), 63–68 (2011).
   Google Scholar
• Nyberg F, Fransson J, Stephansson E. Proliferation and effects of UVA irradiation in cultured fibroblasts from lesions in cutaneous lupus erythematosus. Exp. Dermatol.9(1), 53–57 (2000).
   Google Scholar
• Van Nguyen H, Di Girolamo N, Jackson N et al. Ultraviolet radiation-induced cytokines promote mast cell accumulation and matrix metalloproteinase production: potential role in cutaneous lupus erythematosus. Scand. J. Rheumatol.40(3), 197–204 (2011).
   PubMed Web of Science ®Google Scholar
• Yildirim-Toruner C, Diamond B. Current and novel therapeutics in the treatment of systemic lupus erythematosus. J. Allergy Clin. Immunol.127(2), 303–312; quiz 313–304 (2011).
   PubMed Web of Science ®Google Scholar
• Meller S, Winterberg F, Gilliet M et al. Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: an amplification cycle triggering cutaneous lupus erythematosus. Arthritis Rheum.52(5), 1504–1516 (2005).
   PubMed Web of Science ®Google Scholar
• Wittmann M, Purwar R, Hartmann C, Gutzmer R, Werfel T. Human keratinocytes respond to interleukin-18: implication for the course of chronic inflammatory skin diseases. J. Invest. Dermatol.124(6), 1225–1233 (2005).
   PubMed Web of Science ®Google Scholar
• Baima B, Sticherling M. Apoptosis in different cutaneous manifestations of lupus erythematosus. Br. J. Dermatol.144(5), 958–966 (2001).
   PubMed Web of Science ®Google Scholar
• Wenzel J, Henze S, Worenkamper E et al. Role of the chemokine receptor CCR4 and its ligand thymus- and activation-regulated chemokine/CCL17 for lymphocyte recruitment in cutaneous lupus erythematosus. J. Invest. Dermatol.124(6), 1241–1248 (2005).
   PubMedGoogle Scholar
• Wittmann M, Werfel T. Interaction of keratinocytes with infiltrating lymphocytes in allergic eczematous skin diseases. Curr. Opin. Allergy Clin. Immunol.6(5), 329–334 (2006).
   PubMed Web of Science ®Google Scholar
• Popovic K, Ek M, Espinosa A et al. Increased expression of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in skin lesions of patients with lupus erythematosus. Arthritis Rheum.52(11), 3639–3645 (2005).
   PubMed Web of Science ®Google Scholar
• Wang D, Drenker M, Eiz-Vesper B, Werfel T, Wittmann M. Evidence for a pathogenetic role of interleukin-18 in cutaneous lupus erythematosus. Arthritis Rheum.58(10), 3205–3215 (2008).
   PubMedGoogle Scholar
• Zahn S, Rehkamper C, Kummerer BM et al. Evidence for a pathophysiological role of keratinocyte-derived type III interferon (IFNλ) in cutaneous lupus erythematosus. J. Invest. Dermatol.131(1), 133–140 (2011).
   PubMed Web of Science ®Google Scholar
• Abdulahad DA, Westra J, Limburg PC, Kallenberg CG, Bijl M. HMGB1 in systemic lupus erythematosus: its role in cutaneous lesions development. Autoimmun. Rev.9(10), 661–665 (2010).
   PubMed Web of Science ®Google Scholar
• Sticherling M. Update on the use of topical calcineurin inhibitors in cutaneous lupus erythematosus. Biologics5, 21–31 (2011).
   PubMedGoogle Scholar
• Neurath MF, Finotto S. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev.22(2), 83–89 (2011).
   PubMed Web of Science ®Google Scholar
• Kruse K, Janko C, Urbonaviciute V et al. Inefficient clearance of dying cells in patients with SLE: anti-dsDNA autoantibodies, MFG-E8, HMGB-1 and other players. Apoptosis15(9), 1098–1113 (2010).
   PubMed Web of Science ®Google Scholar
• Shao WH, Cohen PL. Disturbances of apoptotic cell clearance in systemic lupus erythematosus. Arthritis Res. Ther.13(1), 202 (2011).
   PubMed Web of Science ®Google Scholar
• Munoz LE, Lauber K, Schiller M, Manfredi AA, Herrmann M. The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat. Rev. Rheumatol.6(5), 280–289 (2010).
   PubMed Web of Science ®Google Scholar
• Chen Gy, Nunez G. Sterile inflammation: sensing and reacting to damage. Nat. Rev. Immunol.10(12), 826–837 (2010).
   PubMed Web of Science ®Google Scholar
• Urbonaviciute V, Furnrohr BG, Meister S et al. Induction of inflammatory and immune responses by HMGB1–nucleosome complexes: implications for the pathogenesis of SLE. J. Exp. Med.205(13), 3007–3018 (2008).
   PubMed Web of Science ®Google Scholar
• Voll RE, Urbonaviciute V, Furnrohr B, Herrmann M, Kalden JR. The role of high-mobility group box 1 protein in the pathogenesis of autoimmune diseases. Curr. Rheumatol. Rep.10(5), 341–342 (2008).
   Google Scholar
• Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu. Rev. Immunol.28, 367–388 (2010).
   PubMed Web of Science ®Google Scholar
• Lande R, Ganguly D, Facchinetti V et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA–peptide complexes in systemic lupus erythematosus. Sci. Transl. Med.3(73), 73ra19 (2011).
   PubMed Web of Science ®Google Scholar
• Lande R, Gregorio J, Facchinetti V et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature449(7162), 564–569 (2007).
   PubMed Web of Science ®Google Scholar
• Fang S, Zeng F, Guo Q. Comparative proteomics analysis of cytokeratin and involucrin expression in lesions from patients with systemic lupus erythematosus. Acta Biochim. Biophys. Sin. (Shanghai)40(12), 989–995 (2008).
   Google Scholar
• Ghoreishi M, Katayama I, Yokozeki H, Nishioka K. Analysis of 70 kD heat shock protein (HSP70) expression in the lesional skin of lupus erythematosus (LE) and LE related diseases. J. Dermatol.20(7), 400–405 (1993).
   Google Scholar
• Villalobos-Hurtado R, Sanchez-Rogriguez SH, Avalos-Diaz E, Herrera-Esparza R. Possible role of HSP70 in autoantigen shuttling to the dermo–epidermal junction in systemic lupus erythematosus. Reumatismo55(3), 155–158 (2003).
   Google Scholar
• Loser K, Vogl T, Voskort M et al. The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells. Nat. Med.16(6), 713–717 (2010).
   PubMed Web of Science ®Google Scholar
• Tveita AA. The danger model in deciphering autoimmunity. Rheumatology (Oxford)49(4), 632–639 (2010).
   PubMedGoogle Scholar
• Barkauskaite V, Ek M, Popovic K, Harris HE, Wahren-Herlenius M, Nyberg F. Translocation of the novel cytokine HMGB1 to the cytoplasm and extracellular space coincides with the peak of clinical activity in experimentally UV-induced lesions of cutaneous lupus erythematosus. Lupus16(10), 794–802 (2007).
   Google Scholar
• Hreggvidsdottir HS, Ostberg T, Wahamaa H et al. The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. J. Leukoc. Biol.86(3), 655–662 (2009).
   PubMed Web of Science ®Google Scholar
• Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu. Rev. Immunol.28, 367–388 (2010).
   PubMed Web of Science ®Google Scholar
• Kuhn A, Herrmann M, Kleber S et al. Accumulation of apoptotic cells in the epidermis of patients with cutaneous lupus erythematosus after ultraviolet irradiation. Arthritis Rheum.54(3), 939–950 (2006).
   PubMed Web of Science ®Google Scholar
• Wang D, Eiz-Vesper B, Zeitvogel J, Dressel R, Werfel T, Wittmann M. Human keratinocytes release high levels of inducible heat shock protein 70 which enhances peptide uptake. Exp. Dermatol. DOI: 10.1111/j.1600-0625.2011.01287.x (Epub ahead of print).
   Google Scholar
• Figueiredo C, Wittmann M, Wang D et al. Heat shock protein 70 (HSP70) induces cytotoxicity of T-helper cells. Blood113(13), 3008–3016 (2009).
   PubMedGoogle Scholar
• Kreuter A, Jaouhar M, Skrygan M et al. Expression of antimicrobial peptides in different subtypes of cutaneous lupus erythematosus. J. Am. Acad. Dermatol.65(1), 125–133 (2011).
   PubMedGoogle Scholar
• Yousefi S, Gold JA, Andina N et al. Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense. Nat. Med.14(9), 949–953 (2008).
   PubMed Web of Science ®Google Scholar
• Banchereau J, Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity25(3), 383–392 (2006).
   PubMed Web of Science ®Google Scholar
• Pascual V, Farkas L, Banchereau J. Systemic lupus erythematosus: all roads lead to type I interferons. Curr. Opin. Immunol.18(6), 676–682 (2006).
   PubMed Web of Science ®Google Scholar
• Wenzel J, Zahn S, Bieber T, Tuting T. Type I interferon-associated cytotoxic inflammation in cutaneous lupus erythematosus. Arch. Dermatol. Res.301(1), 83–86 (2009).
   PubMed Web of Science ®Google Scholar
• Hall JC, Rosen A. Type I interferons: crucial participants in disease amplification in autoimmunity. Nat. Rev. Rheumatol.6(1), 40–49 (2010).
   PubMed Web of Science ®Google Scholar
• Meyer O. Interferons and autoimmune disorders. Joint Bone Spine76(5), 464–473 (2009).
   PubMed Web of Science ®Google Scholar
• Fah J, Pavlovic J, Burg G. Expression of MxA protein in inflammatory dermatoses. J. Histochem. Cytochem.43(1), 47–52 (1995).
   PubMed Web of Science ®Google Scholar
• Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL. Plasmacytoid dendritic cells (natural interferon-α/β-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am. J. Pathol.159(1), 237–243 (2001).
   PubMed Web of Science ®Google Scholar
• Vermi W, Lonardi S, Morassi M et al. Cutaneous distribution of plasmacytoid dendritic cells in lupus erythematosus. Selective tropism at the site of epithelial apoptotic damage. Immunobiology214(9–10), 877–886 (2009).
   PubMed Web of Science ®Google Scholar
• Wenzel J, Uerlich M, Worrenkamper E, Freutel S, Bieber T, Tuting T. Scarring skin lesions of discoid lupus erythematosus are characterized by high numbers of skin-homing cytotoxic lymphocytes associated with strong expression of the type I interferon-induced protein MxA. Br. J. Dermatol.153(5), 1011–1015 (2005).
   PubMed Web of Science ®Google Scholar
• Wenzel J, Zahn S, Mikus S, Wiechert A, Bieber T, Tuting T. The expression pattern of interferon-inducible proteins reflects the characteristic histological distribution of infiltrating immune cells in different cutaneous lupus erythematosus subsets. Br. J. Dermatol.157(4), 752–757 (2007).
   PubMed Web of Science ®Google Scholar
• Naschberger E, Wenzel J, Kretz CC, Herrmann M, Sturzl M, Kuhn A. Increased expression of guanylate binding protein-1 in lesional skin of patients with cutaneous lupus erythematosus. Exp. Dermatol.20(2), 102–106 (2011).
   Google Scholar
• Reefman E, Kuiper H, Limburg PC, Kallenberg CG, Bijl M. Type I interferons are involved in the development of ultraviolet B-induced inflammatory skin lesions in systemic lupus erythaematosus patients. Ann. Rheum. Dis.67(1), 11–18 (2008).
   PubMed Web of Science ®Google Scholar
• Witte K, Witte E, Sabat R, Wolk K. IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties. Cytokine Growth Factor Rev.21(4), 237–251 (2010).
   PubMed Web of Science ®Google Scholar
• Witte K, Gruetz G, Volk HD et al. Despite IFN-λ receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun.10(8), 702–714 (2009).
   PubMed Web of Science ®Google Scholar
• Wenzel J, Worenkamper E, Freutel S et al. Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus. J. Pathol.205(4), 435–442 (2005).
   PubMed Web of Science ®Google Scholar
• Albanesi C, Scarponi C, Giustizieri ML, Girolomoni G. Keratinocytes in inflammatory skin diseases. Curr. Drug Targets Inflamm. Allergy4(3), 329–334 (2005).
   PubMedGoogle Scholar
• Trautmann A, Akdis M, Schmid-Grendelmeier P et al. Targeting keratinocyte apoptosis in the treatment of atopic dermatitis and allergic contact dermatitis. J. Allergy Clin. Immunol.108(5), 839–846 (2001).
   PubMed Web of Science ®Google Scholar
• Ardern-Jones MR, Black AP, Bateman EA, Ogg GS. Bacterial superantigen facilitates epithelial presentation of allergen to T helper 2 cells. Proc. Natl Acad. Sci. USA104(13), 5557–5562 (2007).
   PubMed Web of Science ®Google Scholar
• Black AP, Ardern-Jones MR, Kasprowicz V et al. Human keratinocyte induction of rapid effector function in antigen-specific memory CD4+ and CD8+ T cells. Eur. J. Immunol.37(6), 1485–1493 (2007).
   Google Scholar
• Albanesi C, Cavani A, Girolomoni G. Interferon-γ-stimulated human keratinocytes express the genes necessary for the production of peptide-loaded MHC class II molecules. J. Invest. Dermatol.110(2), 138–142 (1998).
   PubMed Web of Science ®Google Scholar
• Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus. Science294(5546), 1540–1543 (2001).
   PubMed Web of Science ®Google Scholar
• Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (α/β) in immunity and autoimmunity. Annu. Rev. Immunol.23, 307–336 (2005).
   PubMed Web of Science ®Google Scholar
• Blomberg S, Eloranta ML, Magnusson M, Alm GV, Ronnblom L. Expression of the markers BDCA-2 and BDCA-4 and production of interferon-α by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Rheum.48(9), 2524–2532 (2003).
   PubMed Web of Science ®Google Scholar
• Richards KH, Macdonald A. Putting the brakes on the anti-viral response: negative regulators of type I interferon (IFN) production. Microbes Infect.13(4), 291–302 (2011).
   Google Scholar
• Li J, Fu Q, Cui H et al. Interferon-α priming promotes lipid uptake and macrophage-derived foam cell formation: a novel link between interferon-α and atherosclerosis in lupus. Arthritis Rheum.63(2), 492–502 (2011).
   PubMedGoogle Scholar
• Kaplan MJ, Salmon JE. How does interferon-α insult the vasculature? Let me count the ways. Arthritis Rheum.63(2), 334–336 (2011).
   Google Scholar
• Naschberger E, Croner RS, Merkel S et al. Angiostatic immune reaction in colorectal carcinoma: impact on survival and perspectives for antiangiogenic therapy. Int. J. Cancer123(9), 2120–2129 (2008).
   PubMed Web of Science ®Google Scholar
• Song LL, Ponomareva L, Shen H, Duan X, Alimirah F, Choubey D. Interferon-inducible IFI16, a negative regulator of cell growth, down-regulates expression of human telomerase reverse transcriptase (hTERT) gene. PLoS One5(1), e8569 (2010).
   PubMedGoogle Scholar
• Zeitvogel J, Werfel T, Wittmann M. Keratinocytes enriched for epidermal stem cells differ in their response to IFN-γ from other proliferative keratinocytes. Exp. Dermatol.17(12), 998–1003 (2008).
   Google Scholar
• Al-Refu K, Goodfield M. Hair follicle stem cells in the pathogenesis of the scarring process in cutaneous lupus erythematosus. Autoimmun. Rev.8(6), 474–477 (2009).
   PubMedGoogle Scholar
• Decker P, Singh-Jasuja H, Haager S, Kotter I, Rammensee HG. Nucleosome, the main autoantigen in systemic lupus erythematosus, induces direct dendritic cell activation via a MyD88-independent pathway: consequences on inflammation. J. Immunol.174(6), 3326–3334 (2005).
   PubMed Web of Science ®Google Scholar
• Pisetsky DS. HMGB1: a dangerous player in lupus pathogenesis. J. Rheumatol.37(4), 689–691 (2010).
   Google Scholar
• Unterholzner L, Keating SE, Baran M et al. IFI16 is an innate immune sensor for intracellular DNA. Nat. Immunol.11(11), 997–1004 (2010).
   PubMed Web of Science ®Google Scholar
• Barber GN. Innate immune DNA sensing pathways: STING, AIMII and the regulation of interferon production and inflammatory responses. Curr. Opin. Immunol.23(1), 10–20 (2011).
   PubMed Web of Science ®Google Scholar
• Lee-Kirsch MA, Chowdhury D, Harvey S et al. A mutation in TREX1 that impairs susceptibility to granzyme A-mediated cell death underlies familial chilblain lupus. J. Mol. Med.85(5), 531–537 (2007).
   PubMed Web of Science ®Google Scholar
• Lee-Kirsch MA, Gong M, Chowdhury D et al. Mutations in the gene encoding the 3´-5´ DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat. Genet.39(9), 1065–1067 (2007).
   PubMed Web of Science ®Google Scholar
• Levine D, Switlyk SA, Gottlieb A. Cutaneous lupus erythematosus and anti-TNF-α therapy: a case report with review of the literature. J. Drugs Dermatol.9(10), 1283–1287 (2010).
   PubMed Web of Science ®Google Scholar
• Bave U, Alm GV, Ronnblom L. The combination of apoptotic U937 cells and lupus IgG is a potent IFN-α inducer. J. Immunol.165(6), 3519–3526 (2000).
   PubMed Web of Science ®Google Scholar
• Deng Y, Tsao BP. Genetic susceptibility to systemic lupus erythematosus in the genomic era. Nat. Rev. Rheumatol.6(12), 683–692 (2010).
   PubMed Web of Science ®Google Scholar
• Jarvinen TM, Hellquist A, Koskenmies S et al. Tyrosine kinase 2 and interferon regulatory factor 5 polymorphisms are associated with discoid and subacute cutaneous lupus erythematosus. Exp. Dermatol.19(2), 123–131 (2010).
   PubMed Web of Science ®Google Scholar
• Yao Y, Richman L, Higgs BW et al. Neutralization of interferon-α/β-inducible genes and downstream effect in a phase I trial of an anti-interferon-α monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum.60(6), 1785–1796 (2009).
   PubMed Web of Science ®Google Scholar
• Kuznik A, Bencina M, Svajger U, Jeras M, Rozman B, Jerala R. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J. Immunol.186(8), 4794–4804 (2011).
   PubMed Web of Science ®Google Scholar
• Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y. Hydroxychloroquine: from malaria to autoimmunity. Clin. Rev. Allergy Immunol. DOI: 10.1007/s12016-010-8243-x (2011) (Epub ahead of print).
   Google Scholar
• Sjolin-Forsberg G, Berne B, Eggelte TA, Karlsson-Parra A. In situ localization of chloroquine and immunohistological studies in UVB-irradiated skin of photosensitive patients. Acta Derm. Venereol.75(3), 228–231 (1995).
   Google Scholar
• Dickie LJ, Church LD, Coulthard LR, Mathews RJ, Emery P, McDermott MF. Vitamin D3 down-regulates intracellular Toll-like receptor 9 expression and Toll-like receptor 9-induced IL-6 production in human monocytes. Rheumatology (Oxford)49(8), 1466–1471 (2010).
   PubMed Web of Science ®Google Scholar
• Wenzel J, Tuting T. An IFN-associated cytotoxic cellular immune response against viral, self-, or tumor antigens is a common pathogenetic feature in ‘interface dermatitis’. J. Invest. Dermatol.128(10), 2392–2402 (2008).
   PubMedGoogle Scholar
• Vanbervliet B, Bendriss-Vermare N, Massacrier C et al. The inducible CXCR3 ligands control plasmacytoid dendritic cell responsiveness to the constitutive chemokine stromal cell-derived factor 1 (SDF-1)/CXCL12. J. Exp. Med.198(5), 823–830 (2003).
   PubMed Web of Science ®Google Scholar
• Klunker S, Trautmann A, Akdis M et al. A second step of chemotaxis after transendothelial migration: keratinocytes undergoing apoptosis release IFN-γ-inducible protein 10, monokine induced by IFN-γ, and IFN-γ-inducible α-chemoattractant for T cell chemotaxis toward epidermis in atopic dermatitis. J. Immunol.171(2), 1078–1084 (2003).
   PubMed Web of Science ®Google Scholar
• De Palma G, Castellano G, Del Prete A et al. The possible role of ChemR23/chemerin axis in the recruitment of dendritic cells in lupus nephritis. Kidney Int.79(11), 1228–1235 (2011).
   Google Scholar
• Wittamer V, Franssen JD, Vulcano M et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J. Exp. Med.198(7), 977–985 (2003).
   PubMed Web of Science ®Google Scholar
• Vermi W, Riboldi E, Wittamer V et al. Role of ChemR23 in directing the migration of myeloid and plasmacytoid dendritic cells to lymphoid organs and inflamed skin. J. Exp. Med.201(4), 509–515 (2005).
   PubMed Web of Science ®Google Scholar
• Guillabert A, Wittamer V, Bondue B et al. Role of neutrophil proteinase 3 and mast cell chymase in chemerin proteolytic regulation. J. Leukoc. Biol.84(6), 1530–1538 (2008).
   Google Scholar
• Albanesi C, Scarponi C, Pallotta S et al. Chemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitment. J. Exp. Med.206(1), 249–258 (2009).
   PubMed Web of Science ®Google Scholar
• Skrzeczynska-Moncznik J, Wawro K, Stefanska A et al. Potential role of chemerin in recruitment of plasmacytoid dendritic cells to diseased skin. Biochem. Biophys. Res. Commun.380(2), 323–327 (2009).
   PubMed Web of Science ®Google Scholar
• Gutzmer R, Kother B, Zwirner J et al. Human plasmacytoid dendritic cells express receptors for anaphylatoxins C3a and C5a and are chemoattracted to C3a and C5a. J. Invest. Dermatol.126(11), 2422–2429 (2006).
   PubMedGoogle Scholar
• Tanasescu C, Balanescu E, Balanescu P et al. IL-17 in cutaneous lupus erythematosus. Eur. J. Intern. Med.21(3), 202–207 (2010).
   PubMed Web of Science ®Google Scholar
• Larsen JM, Bonefeld CM, Poulsen SS, Geisler C, Skov L. IL-23 and T(H)17-mediated inflammation in human allergic contact dermatitis. J. Allergy Clin. Immunol.123(2), 486–492 (2009).
   PubMed Web of Science ®Google Scholar
• Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: overview and update. J. Am. Acad. Dermatol.45(3), 420–434 (2001).
   PubMed Web of Science ®Google Scholar
• Favilli F, Anzilotti C, Martinelli L et al. IL-18 activity in systemic lupus erythematosus. Ann. NY Acad. Sci.1173, 301–309 (2009).
   Google Scholar
• Wittmann M, Macdonald A, Renne J. IL-18 and skin inflammation. Autoimmun. Rev.9(1), 45–48 (2009).
   PubMed Web of Science ®Google Scholar
• Kanda N, Shimizu T, Tada Y, Watanabe S. IL-18 enhances IFN-γ-induced production of CXCL9, CXCL10, and CXCL11 in human keratinocytes. Eur. J. Immunol.37(2), 338–350 (2007).
   PubMed Web of Science ®Google Scholar
• Hu D, Liu X, Chen S, Bao C. Expressions of IL-18 and its binding protein in peripheral blood leukocytes and kidney tissues of lupus nephritis patients. Clin. Rheumatol.29(7), 717–721 (2010).
   Google Scholar
• Novick D, Elbirt D, Miller G, Dinarello CA, Rubinstein M, Sthoeger ZM. High circulating levels of free interleukin-18 in patients with active SLE in the presence of elevated levels of interleukin-18 binding protein. J. Autoimmun.34(2), 121–126 (2010).
   PubMed Web of Science ®Google Scholar
• Dorner T, Hucko M, Mayet WJ, Trefzer U, Burmester GR, Hiepe F. Enhanced membrane expression of the 52 kDa Ro(SS-A) and La(SS-B) antigens by human keratinocytes induced by TNF α. Ann. Rheum. Dis.54(11), 904–909 (1995).
   Google Scholar
• Casciola-Rosen L, Rosen A. Ultraviolet light-induced keratinocyte apoptosis: a potential mechanism for the induction of skin lesions and autoantibody production in LE. Lupus6(2), 175–180 (1997).
   PubMed Web of Science ®Google Scholar
• Werth VP, Zhang W, Dortzbach K, Sullivan K. Association of a promoter polymorphism of tumor necrosis factor-α with subacute cutaneous lupus erythematosus and distinct photoregulation of transcription. J. Invest. Dermatol.115(4), 726–730 (2000).
   PubMedGoogle Scholar
• Millard TP, Kondeatis E, Cox A et al. A candidate gene analysis of three related photosensitivity disorders: cutaneous lupus erythematosus, polymorphic light eruption and actinic prurigo. Br. J. Dermatol.145(2), 229–236 (2001).
   Google Scholar
• Aringer M, Smolen Js. TNF inhibition in SLE: where do we stand? Lupus18(1), 5–8 (2009).
   PubMed Web of Science ®Google Scholar
• Lu KQ, Brenneman S, Burns R Jr et al. Thalidomide inhibits UVB-induced mouse keratinocyte apoptosis by both TNF-α-dependent and TNF-α-independent pathways. Photodermatol. Photoimmunol. Photomed.19(6), 272–280 (2003).
   Google Scholar
• Seneschal J, Milpied B, Vergier B, Lepreux S, Schaeverbeke T, Taieb A. Cytokine imbalance with increased production of interferon-α in psoriasiform eruptions associated with antitumour necrosis factor-α treatments. Br. J. Dermatol.161(5), 1081–1088 (2009).
   PubMed Web of Science ®Google Scholar
• Palucka AK, Blanck JP, Bennett L, Pascual V, Banchereau J. Cross-regulation of TNF and IFN-α in autoimmune diseases. Proc. Natl Acad. Sci. USA102(9), 3372–3377 (2005).
   PubMed Web of Science ®Google Scholar
• Bave U, Vallin H, Alm GV, Ronnblom L. Activation of natural interferon-α producing cells by apoptotic U937 cells combined with lupus IgG and its regulation by cytokines. J. Autoimmun.17(1), 71–80 (2001).
   PubMed Web of Science ®Google Scholar
• Sturfelt G, Roux-Lombard P, Wollheim FA, Dayer JM. Low levels of interleukin-1 receptor antagonist coincide with kidney involvement in systemic lupus erythematosus. Br. J. Rheumatol.36(12), 1283–1289 (1997).
   PubMedGoogle Scholar
• Brugos B, Kiss E, Dul C et al. Measurement of interleukin-1 receptor antagonist in patients with systemic lupus erythematosus could predict renal manifestation of the disease. Hum. Immunol.71(9), 874–877 (2010).
   Google Scholar
• Abe M, Shimizu A, Yokoyama Y, Takeuchi Y, Ishikawa O. A possible inhibitory action of diaminodiphenyl sulfone on tumour necrosis factor-α production from activated mononuclear cells on cutaneous lupus erythematosus. Clin. Exp. Dermatol.33(6), 759–763 (2008).
   PubMed Web of Science ®Google Scholar
• Wozniacka A, Lesiak A, Boncela J, Smolarczyk K, Mccauliffe DP, Sysa-Jedrzejowska A. The influence of antimalarial treatment on IL-1β, IL-6 and TNF-α mRNA expression on UVB-irradiated skin in systemic lupus erythematosus. Br. J. Dermatol.159(5), 1124–1130 (2008).
   PubMed Web of Science ®Google Scholar
• Wozniacka A, Lesiak A, Narbutt J, McCauliffe DP, Sysa-Jedrzejowska A. Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients. Lupus15(5), 268–275 (2006).
   PubMed Web of Science ®Google Scholar
• Horwitz DA, Gray JD, Behrendsen SC et al. Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus. Arthritis Rheum.41(5), 838–844 (1998).
   PubMed Web of Science ®Google Scholar
• Liu TF, Jones BM. Impaired production of IL-12 in system lupus erythematosus. II: IL-12 production in vitro is correlated negatively with serum IL-10, positively with serum IFN-γ and negatively with disease activity in SLE. Cytokine10(2), 148–153 (1998).
   PubMedGoogle Scholar
• Tsai CY, Wu TH, Yu CL, Tsai YY, Chou CT. Decreased IL-12 production by polymorphonuclear leukocytes in patients with active systemic lupus erythematosus. Immunol. Invest.31(3–4), 177–189 (2002).
   PubMed Web of Science ®Google Scholar
• Werth VP, Bashir MM, Zhang W. IL-12 completely blocks ultraviolet-induced secretion of tumor necrosis factor α from cultured skin fibroblasts and keratinocytes. J. Invest. Dermatol.120(1), 116–122 (2003).
   Google Scholar
• Schwarz A, Stander S, Berneburg M et al. Interleukin-12 suppresses ultraviolet radiation-induced apoptosis by inducing DNA repair. Nat. Cell Biol.4(1), 26–31 (2002).
   PubMed Web of Science ®Google Scholar
• Nurnberg W, Haas N, Schadendorf D, Czarnetzki BM. Interleukin-6 expression in the skin of patients with lupus erythematosus. Exp. Dermatol.4(1), 52–57 (1995).
   Google Scholar
• Illei GG, Shirota Y, Yarboro CH et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label Phase I dosage-escalation study. Arthritis Rheum.62(2), 542–552 (2010).
   PubMed Web of Science ®Google Scholar
• Kido M, Takeuchi S, Sugiyama N et al. T cell-specific overexpression of interleukin-27 receptor α-subunit (WSX-1) prevents spontaneous skin inflammation in MRL/lpr mice. Br. J. Dermatol.164(6), 1214–1220 (2011).
   PubMed Web of Science ®Google Scholar
• Sugiyama N, Nakashima H, Yoshimura T et al. Amelioration of human lupus-like phenotypes in MRL/lpr mice by overexpression of interleukin 27 receptor α (WSX-1). Ann. Rheum. Dis.67(10), 1461–1467 (2008).
   PubMed Web of Science ®Google Scholar
• Li TT, Zhang T, Chen GM et al. Low level of serum interleukin 27 in patients with systemic lupus erythematosus. J. Investig. Med.58(5), 737–739 (2010).
   PubMed Web of Science ®Google Scholar
• Llorente L, Richaud-Patin Y. The role of interleukin-10 in systemic lupus erythematosus. J. Autoimmun.20(4), 287–289 (2003).
   PubMed Web of Science ®Google Scholar
• Llorente L, Richaud-Patin Y, Garcia-Padilla C et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum.43(8), 1790–1800 (2000).
   PubMed Web of Science ®Google Scholar
• Ruan BH, Li X, Winkler AR et al. Complement C3a, CpG oligos, and DNA/C3a complex stimulate IFN-α production in a receptor for advanced glycation end product-dependent manner. J. Immunol.185(7), 4213–4222 (2010).
   PubMed Web of Science ®Google Scholar
• Purwar R, Wittmann M, Zwirner J et al. Induction of C3 and CCL2 by C3a in keratinocytes: a novel autocrine amplification loop of inflammatory skin reactions. J. Immunol.177(7), 4444–4450 (2006).
   Google Scholar
• Thacker SG, Berthier CC, Mattinzoli D, Rastaldi MP, Kretzler M, Kaplan MJ. The detrimental effects of IFN-α on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction. J. Immunol.185(7), 4457–4469 (2010).
   PubMed Web of Science ®Google Scholar
• Jarvinen TM, Hellquist A, Koskenmies S et al. Polymorphisms of the ITGAM gene confer higher risk of discoid cutaneous than of systemic lupus erythematosus. PLoS One5(12), e14212 (2010).
   PubMedGoogle Scholar